Login / Signup

Asenapine add-on treatment for schizophrenia adults who received antipsychotics: A 52-week, open-label study.

Taro KishiYasuhiro IwamaYuji SasagawaShuichi HiraokaAya KameiNakao Iwata
Published in: Psychiatry and clinical neurosciences (2023)
Keyphrases
  • open label
  • bipolar disorder
  • clinical trial
  • squamous cell carcinoma
  • phase iii
  • double blind